NYSE · Medical - Devices

Glaukos Corporation (GKOS) Stock

$178.88 +1.24% NYSE: GKOS Healthcare

Valuation

MetricValue
Price$178.88
Market Cap$10.55B
P/E Ratio-50.38
P/B Ratio14.02
P/S Ratio15.76
EPS (TTM)$-3.28
52-Week High$191.62
52-Week Low$73.16
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-27.07%
ROA-20.43%
ROCE-9.84%
Gross Margin-17.16%
Operating Margin-17.16%
Net Margin-30.68%
Debt/Equity0.15
Current Ratio4.70

Annual Financials (USD)

Metric20212022202320242025
Revenue$294.0M$283.0M$315.0M$383.0M$507.0M
Operating Profit$-33.0M$-82.0M$-129.0M$-122.0M$-87.0M
Net Profit$-50.0M$-99.0M$-135.0M$-146.0M$-188.0M
EPS$-1.07$-2.09$-2.78$-2.77$-3.28
Op Margin-11.2%-29.1%-40.9%-31.9%-17.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$1.1B$940.0M$975.0M$893.0M
Total Liabilities$542.0M$544.0M$479.0M$208.0M$237.0M
Cash$101.0M$120.0M$93.0M$170.0M$91.0M
Borrowings$383.0M$383.0M$384.0M$103.0M$140.0M

Latest News

Truist Adjusts Price Target on Glaukos to $180 From $160, Maintains Buy Rating MT Newswires · Jul 16, 2026 GKOS: Raising target price to $160.00 Argus Research · Jul 15, 2026 Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now? Motley Fool · Jul 14, 2026 Glaukos Insider Sold Shares Worth $1,550,000, According to a Recent SEC Filing MT Newswires · Jul 14, 2026 Glaukos Insider Sold Shares Worth $1,500,000, According to a Recent SEC Filing MT Newswires · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$25.0M$-33.0M$-58.0M$-61.0M$-46.0M
Investing Cash Flow$-106.0M$15.0M$-6.0M$42.0M$-85.0M
Financing Cash Flow$9.0M$-2.0M$-3.0M$-7.0M$-8.0M
Net Cash Flow$4.0M$19.0M$-26.0M$76.0M$-111.0M
Free Cash Flow$-23.0M$-63.0M$-78.0M$-68.0M$-54.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.45
EV / EBITDA-67.81
FCF Yield-0.13%
Quick Ratio4.46
Interest Coverage-16.41
Return 1Y90.40%
Return 3Y128.63%
Return 5Y251.66%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALCAlcon Inc. $70.17 -0.65% 50.34 $33.92B 0.55%
BLCOBausch + Lomb Corporation $17.47 +0.23% -35.85 $6.24B 0.00%
EYPTEyePoint, Inc. $0.40 -5.51% -0.91 $33.91M 0.00%
IRIXIRIDEX Corporation $0.75 -2.18% -3.16 $13.10M 0.00%
OCULOcular Therapeutix, Inc. $6.50 -1.66% -5.56 $1.43B 0.00%

About Glaukos Corporation

Glaukos Corporation is led by CEO Thomas William Burns, employs 1,094 people, headquartered in Aliso Viejo, US, publicly traded since 2015.

Glaukos Corporation (GKOS) stock trades at $178.88 with a market capitalization of $10.55B. The stock is valued at a negative price-to-earnings (P/E) ratio of -50.38, reflecting a net loss over the last twelve months, price-to-book of 14.02, price-to-sales of 15.76. Over the past 52 weeks the stock has ranged between $73.16 and $191.62, and currently trades 6.6% below its 52-week high.

On profitability, Glaukos Corporation generates a return on equity (ROE) of -27.07% (negative, reflecting a net loss), return on capital employed of -9.84%, an operating margin of -17.16%, a net profit margin of -30.68%.

Glaukos Corporation by the numbers, 2016–2025

Between 2016 and 2025 Glaukos Corporation reported revenue of $114.0M rising to $507.0M, a change of +344.7% across 10 years. Compounded, revenue has grown 17.6% a year over five years, 21.4% over three, 32.4% over the last twelve months. Net profit fell to $-188.0M.

Operating margin went from 3.7% in 2016 to -17.1% in 2025, a fall of 20.8 percentage points. The most recent net margin is -30.68%. On a trailing twelve-month basis to Jun '26, revenue is $614.0M and net profit $-188.0M.

Borrowings stand at $140.0M, cash from operations was $-46.0M in the latest year, positive in 4 of the last 10.

Return on equity has averaged -20.8% over five years, and was -28.7% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Glaukos Corporation (GKOS) — frequently asked questions

What is Glaukos Corporation (GKOS) stock price today?

Glaukos Corporation (GKOS) is currently trading at $178.88, up 1.24% today.

What is GKOS P/E ratio?

Glaukos Corporation's P/E ratio is -50.38. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is GKOS return on equity (ROE)?

Glaukos Corporation's return on equity (ROE) is -27.07%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Glaukos Corporation's market cap?

Glaukos Corporation has a market capitalization of $10.55B.

Does GKOS pay a dividend?

Glaukos Corporation is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does GKOS carry?

Glaukos Corporation has a debt-to-equity ratio of 0.15. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is GKOS's profit margin?

Glaukos Corporation reports a net profit margin of -30.68% — the share of revenue left after every cost, including tax and interest.

What sector is GKOS in?

Glaukos Corporation is classified under Healthcare, in the Medical - Devices industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is GKOS listed on?

Glaukos Corporation trades on NYSE under the ticker GKOS.

What is GKOS's 52-week range?

Over the last year Glaukos Corporation has traded between $73.16 and $191.62.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens GKOS currently matches

On the figures above, Glaukos Corporation passes the filters for 6 of our ready-made screens, among them Low Debt Stocks, Large Cap Stocks, NYSE Listed Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Low Debt StocksLarge Cap StocksNYSE Listed StocksDebt to Equity Below 1 StocksHigh Current Ratio StocksLow Debt Large Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.